CALOGERA MARIA SIMONARO

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. pmc Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI
    Efrat Eliyahu
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York, United States of America
    PLoS ONE 6:e22447. 2011
  2. pmc Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses
    Edward H Schuchman
    Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York, United States of America
    PLoS ONE 8:e54459. 2013
  3. ncbi request reprint Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses
    C M Simonaro
    Department of Human Genetics, Mount Sinai School of Medicine, New York, New York 10029, USA
    Lab Invest 81:1319-28. 2001
  4. ncbi request reprint Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models
    Calogera M Simonaro
    Department of Human Genetics, Mount Sainai School of Medicine, New York, NY 10029, USA
    Pediatr Res 57:701-7. 2005
  5. pmc Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases
    Calogera M Simonaro
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, 1425 Madison Ave, New York, NY, 10029, USA
    Am J Pathol 172:112-22. 2008
  6. pmc Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses
    Calogera M Simonaro
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 107:222-7. 2010
  7. pmc Imprinting at the SMPD1 locus: implications for acid sphingomyelinase-deficient Niemann-Pick disease
    Calogera M Simonaro
    Department of Human Genetics, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Hum Genet 78:865-70. 2006

Research Grants

  1. Novel Therapies and Biomarkers for the Mucopolysaccharidoses
    CALOGERA MARIA SIMONARO; Fiscal Year: 2010

Collaborators

Detail Information

Publications7

  1. pmc Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI
    Efrat Eliyahu
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York, United States of America
    PLoS ONE 6:e22447. 2011
    ....
  2. pmc Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses
    Edward H Schuchman
    Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York, United States of America
    PLoS ONE 8:e54459. 2013
    ..Enzyme replacement therapy (ERT) only partly reduced inflammation, and anti-TNF-alpha antibody therapy significantly enhanced clinical and pathological outcomes. Here we describe the use of PPS for the treatment of MPS type VI rats...
  3. ncbi request reprint Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses
    C M Simonaro
    Department of Human Genetics, Mount Sinai School of Medicine, New York, New York 10029, USA
    Lab Invest 81:1319-28. 2001
    ..In turn, this leads to abnormal cartilage matrix homeostasis in the MPS individuals, which further exacerbates the joint deformities characteristic of these disorders...
  4. ncbi request reprint Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models
    Calogera M Simonaro
    Department of Human Genetics, Mount Sainai School of Medicine, New York, NY 10029, USA
    Pediatr Res 57:701-7. 2005
    ..This information should aid in the evaluation of existing therapies for these disorders, such as enzyme replacement therapy and bone marrow transplantation, and may lead to the development of new therapeutic approaches...
  5. pmc Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases
    Calogera M Simonaro
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, 1425 Madison Ave, New York, NY, 10029, USA
    Am J Pathol 172:112-22. 2008
    ..These findings have important implications for the pathogenesis and treatment of MPS and have further defined the mechanism of GAG-stimulated disease...
  6. pmc Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses
    Calogera M Simonaro
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 107:222-7. 2010
    ..These studies revealed the important role of TLR4 signaling in MPS bone and joint disease and suggest that targeting TNF-alpha may have positive therapeutic effects...
  7. pmc Imprinting at the SMPD1 locus: implications for acid sphingomyelinase-deficient Niemann-Pick disease
    Calogera M Simonaro
    Department of Human Genetics, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Hum Genet 78:865-70. 2006
    ..These data thus demonstrate, for the first time, imprinting at the SMPD1 gene and reveal the influence of this epigenetic modification on the presentation of ASM-deficient NPD...

Research Grants2

  1. Novel Therapies and Biomarkers for the Mucopolysaccharidoses
    CALOGERA MARIA SIMONARO; Fiscal Year: 2010
    ..Thus, new approaches are clearly needed to reduce the disease and economic burden to MPS patients and the societies in which they live. This is the long-term goal of the proposed research ..